Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children

Author(s):  
Gladymar Perez Chacon ◽  
Jessica Ramsay ◽  
Christopher Brennan-Jones ◽  
Marie Estcourt ◽  
Peter Richmond ◽  
...  
Author(s):  
Gladymar Perez Chacon ◽  
Marie Estcourt ◽  
Jessica Ramsay ◽  
Christopher G Brennan-Jones ◽  
Peter Richmond ◽  
...  

Biologicals ◽  
1997 ◽  
Vol 25 (1) ◽  
pp. 41-57 ◽  
Author(s):  
Ineke van Straaten-van de Kappelle ◽  
Johan W. van der Gun ◽  
Frits R. Marsman ◽  
Coenraad F.M. Hendriksen ◽  
Huib J.M. van de Donk

PEDIATRICS ◽  
1988 ◽  
Vol 82 (3) ◽  
pp. 293-299
Author(s):  
Margareta Blennow ◽  
Marta Granström ◽  
Eva Jäätmaa ◽  
Patrick Olin

The rate of adverse reactions and the immunogenicity of a two-component acellular pertussis vaccine as compared with a plain whole-cell vaccine and a placebo were evaluated for primary immunization in 319 6-month-old infants in a double-blind randomized clinical trial. The acellular vaccine produced few and mild systemic and local reactions. Fever (≥38°C) occurred in 6% to 8% of acellular vaccinees as opposed to 25% to 37% of whole-cell vaccinees. Redness (≥1 cm) appeared in 2% to 13% of the acellular vaccine and 24% to 32% of the whole-cell vaccine recipients. Antibody response to pertussis toxin measured in a neutralization test was obtained in 97% to 100% of the infants receiving either two or three doses of the acellular vaccine as compared to 59% after three doses of whole-cell vaccine.


2010 ◽  
Vol 74 (1) ◽  
pp. 150-154 ◽  
Author(s):  
Kumanan Wilson ◽  
Beth Potter ◽  
Douglas Manuel ◽  
Jennifer Keelan ◽  
Pranesh Chakraborty

Biologicals ◽  
2015 ◽  
Vol 43 (2) ◽  
pp. 100-109 ◽  
Author(s):  
M.E. Hoonakker ◽  
L.M. Verhagen ◽  
C.F.M. Hendriksen ◽  
C.A.C.M. van Els ◽  
R.J. Vandebriel ◽  
...  

PEDIATRICS ◽  
1983 ◽  
Vol 71 (2) ◽  
pp. 200-205
Author(s):  
M. Dianne Murphy ◽  
Jeane Rasnack ◽  
Harold D. Dickson ◽  
Marc Dietch ◽  
Philip A. Brunell

The adjuvant and antigen components of the pertussis fraction of diphtheria-tetanus-pertussis (DTP) vaccine were evaluated. Four preparations of DTP vaccine composed of either whole cell (Wc) or extracted (E) pertussis antigen combined with either an aluminum phosphate (Ph) or alum (Al) adjuvant were compared. Local reactions were similar in all four vaccines after the first two immunizations but were significantly increased in incidence and severity following the third immunization with vaccine WcPh. This appeared to be due to the Ph adjuvant rather than the antigen component. Febrile reactions were experienced more often (P = .0009) and with higher temperatures (P = .0001) with the WcPh vaccine following the first immunization. This appeared to be due to the Wc component. Comparing the pooled Wc groups with the pooled E groups revealed a greater febrile response in the Wc group after both the first (P = .0008) and the second (P = .03) immunization. Local reactions appear temporally and etiologically to be distinct from febrile reactions. The pooled Wc antigen group produced a higher geometric mean titer than the pooled E antigen group (P = .05). Serologic responses, with respect to geometric mean titer, were not significantly different among the individual vaccines. This study suggests that the combination of whole cell and aluminum phosphate, which is currently in use in the United States, is probably not the optimal formulation for pertussis vaccine.


Sign in / Sign up

Export Citation Format

Share Document